2025 Year in Review for Science | Revvity Signals

2025 was an extremely remarkable year: Drug development reached a milestone with the first personalized CRISPR-based therapy for a rare disease, while synthetic chemists delivered advances ranging from complex natural products to novel supramolecular architectures. At the same time, AI became even more deeply integrated into pharma, chemistry, and adjacent R&D fields, reshaping how teams design, test, and make decisions.

It was an equally transformative year for Revvity Signals. Building on momentum from 2023 and 2024, our efforts focused on unification of data, domains, and people. From launching new solutions and capabilities to deepening customer collaboration and partner ecosystems, we worked to strengthen the scientific infrastructure that supports modern discovery and development.

Below, we look back on the milestones and initiatives that defined 2025 for Revvity Signals and our global community. 

Celebrating 40 Years of ChemDraw

This year marked the 40th anniversary of ChemDraw, a true milestone for a scientific application that has fundamentally reshaped the way chemistry is communicated. Since its debut at a 1985 Gordon Research Conference, ChemDraw has replaced labor-intensive, hand-drawn structures with precise, standardized digital sketches, quickly becoming the best-in-class application for chemists and democratizing how molecular ideas are visualized and shared.

Over four decades, ChemDraw has evolved from a simple drawing program into a modern, integrated platform. Today, it supports Name-to-Structure conversion, spectral simulation, 3D conformational modeling, and cloud-enabled collaboration through Signals ChemDraw. These advances have made it a foundational resource for cheminformatics, machine-readable chemical formats, and AI-driven discovery.  

Throughout 2025, we highlighted how these ongoing enhancements continue to support contemporary chemistry in our ChemDraw Connect series, reinforcing ChemDraw’s role as a trusted, gold standard visualization platform.

Unifying Data to Accelerate Discovery

As AI and analytics have become foundational for life sciences, chemistry, materials research, and formulation, unified and interoperable data has become a critical requirement. This year, at Bio-IT World, Revvity Signals launched Signals One™, a cloud-native platform designed to span the full “Design-Make-Test-Decide” lifecycle.  

Signals One standardizes assay data, enables advanced curve fitting and group comparisons, and supports seamless information flow across biology, chemistry, materials, and formulation workflows. By addressing fragmented data environments, it lowers barriers to AI adoption and ensures analytics-ready data across R&D.  

Continuous Innovation

In 2025 we laid out our intent to expand our capabilities through targeted acquisition and new to market solutions. Recently, we announced our plans to integrate ACD/Labs technologies into the Revvity Signals platform, a move that will deliver a unified SaaS environment for customers across pharmaceuticals and material sciences. As Kevin Willoe, President of Revvity Signals Software, explained: ‘By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution.’

In 2025 we previewed new solutions, such as Signals BioDesign, an enterprise SaaS for streamlining molecular biology, focusing on core cloning and high-throughput plasmid modeling. Signals BioDesign supports organizations of all sizes, integrating directly within Revvity Signals solutions to enhance collaboration for large-molecule design. Also coming soon on the roadmap is Signals LabGistics, a workflow management solution designed to streamline scientific workflows across the drug development lifecycle. Signals LabGistics allows teams to plan, execute, and monitor tasks while ensuring data flows seamlessly from research and development to production.  

In December we also announced the introduction of the forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence.

Together, these efforts reflect how Revvity Signals is responding to the needs of the scientific community and shaping more powerful solutions that truly meet the needs of our customers now and for the future.

Customer Development and Success 

Customer insights heavily shaped our 2025 roadmap. The Ideas Portal became a key space this year, giving customers a direct line of input into product development.  In 2025 we shipped 17% of submitted ideas, nearly double the industry’s average clearance rate of 10%, demonstrating our commitment to turning customer insights into real-world solutions. Along with the increased guidance we got through the Ideas portal, we shaped the roadmap for 2025 around customer support, feedback, and highlights through virtual and live events across the globe.  

In the virtual space, the Connect Series dove deep into platform capabilities, success stories, and integration strategies. We also published a number of case studies to showcase the real-world impact of our customers and launched our Developer Guide, enabling customers to more effectively leverage the platforms capabilities.

Revvity Signals also hosted NEXUS Europe 2025, bringing together researchers, IT leaders, and digitalization teams for technical deep dives focused on the future of scientific informatics. The take-home message was clear: sustained community collaboration is essential for scaling innovation across modern R&D environments.  

In 2025 we continued to shape events that provided a forum for connection and collaboration, such as our events in Japan, where we hosted Japan NEXUS 2025 and celebrated the 20th year of JASPUG (Japanese Spotfire user group) and our invite only Signals Innovator event which continues to ignite the spark of curiosity and innovation within the community.

Driving Progress with AI  

AI was perhaps the largest story that defined 2025, as it continued (and continues) to reshape scientific discovery and beyond. At Revvity Signals, we are continuing our journey with AI and this year sees the release of features and capabilities that help empower the day to day for scientists everywhere. Semantic search and text‑to‑image extraction in Signals One make it easier for scientists to uncover insights, document experiments, and generate images, freeing up more time to focus on science.

This year, Signals Clinical transformed how teams manage clinical trials. As a cloud-native solution, it brought real-time access to study data, simplifying oversight and accelerating analytics. Industry excitement at SCDM and growing adoption confirmed its impact.

A standout achievement was the launch of our Custom Listings Generator, which empowers teams to create tailored clinical listings in moments-no programming required. Powered by AI, it ensures transparency, reproducibility, and compliance, saving time and resources.

We also advanced knowledge integration and retrieval-augmented generation, enabling faster, more confident decisions based on current study data. By reducing bottlenecks and keeping human judgment at the core, Signals Clinical is helping teams improve patient outcomes.

As we broaden the access of our customers to AI tools within our platforms, our hope is that the democratization of AI will enable a better connection between R&D and clinical domains, driving better communication, insight, and ultimately, translation.

Looking Ahead to 2026 and Beyond

As we look ahead to 2026, Revvity Signals will continue to strengthen the connections that defined 2025, advance platform capabilities across research and clinical domains, expand AI where it delivers meaningful value, and deepen customer collaboration through the Ideas Portal and collaborative consortia and events.  

Partnerships with technology providers and model developers will bring more domain-specific intelligence into context, while customer education initiatives will empower teams to apply these innovations with confidence.  

2026 will be a year of continued unity across data and tools, and importantly with Revvity Signals and the global scientific community we support and innovate for. As we close out 2025, we want to thank our customers and collaborators, for helping us build towards a unified and more integrated future for science. 

We have loved staying in touch with you throughout 2025.  You can contact us for further discussion and sign up for our newsletter to stay up to date with Revvity Signals in 2026.